BIOFORCE NANOSCIENCES HOLDINGS Business Summary

Bioforce Nanosciences Holdings, Inc. (BFNH) operates as a consumer health firm specializing in the development and distribution of natural vitamins, minerals, and nutritional supplements under its BioForce Eclipse brand. The company employs a private-label business model, generating revenue through the sale of nutritional powders and beverages across a multi-channel network that includes mass merchandisers, sporting goods retailers, and supermarkets. Its primary revenue streams are derived from wholesale transactions and direct-to-consumer (DTC) sales facilitated by its e-commerce platform and social media marketing. Currently, the company is positioned as a micro-cap player in the personal products industry, having pivoted from its legacy nanotechnology instrumentation roots to focus on the growing wellness market for athletes and the elderly. BFNH competes directly with established industry peers such as Herbalife Nutrition Ltd., Natural Alternatives International, Inc., Medifast, Inc., and MannKind Corporation, distinguishing itself through a lean operational structure and a focus on niche telemarketing and digital distribution channels. Leadership at BFNH is currently directed by Co-Chief Executive Officers Steve Gagnon and John LaViolette, who were appointed in late 2021 to oversee the company's commercial reorganization and strategic transition. Gagnon possesses a 20-year background in media finance and production, while LaViolette brings extensive corporate and legal expertise from his tenure as a senior partner at a major entertainment law firm; both executives also hold concurrent leadership roles at the affiliated entity Element Global, Inc. The board of directors is led by Chairman Merle Ferguson, a veteran executive who previously served as the company’s President and CEO. Financial oversight is managed by Richard Kaiser, who serves as the Acting CFO, Secretary, and Principal Accounting Officer. This leadership team is focused on navigating the firm’s current financial restructuring, supported by strategic capital infusions from related parties and a focus on expanding the BioForce Eclipse product line into broader domestic retail markets.